Increased levels of MIP‐1α in CSF and serum of ALS
X Yang, L Gao, X Wu, Y Zhang… - Acta Neurologica …, 2016 - Wiley Online Library
X Yang, L Gao, X Wu, Y Zhang, D Zang
Acta Neurologica Scandinavica, 2016•Wiley Online LibraryObjectives Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
with complicated pathogenesis. No effective diagnostic test and cure exists for the disease at
present. We detected the levels of MIP‐1α in cerebrospinal fluid (CSF) and serum and then
further evaluated whether MIP‐1α levels correlate with the severity and progression of ALS.
Methods We used ELISA s to detect MIP‐1α levels from 58 patients with ALS and 45 age‐
and gender‐matched controls. The patients with ALS were also clinically evaluated with the …
with complicated pathogenesis. No effective diagnostic test and cure exists for the disease at
present. We detected the levels of MIP‐1α in cerebrospinal fluid (CSF) and serum and then
further evaluated whether MIP‐1α levels correlate with the severity and progression of ALS.
Methods We used ELISA s to detect MIP‐1α levels from 58 patients with ALS and 45 age‐
and gender‐matched controls. The patients with ALS were also clinically evaluated with the …
Objectives
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with complicated pathogenesis. No effective diagnostic test and cure exists for the disease at present. We detected the levels of MIP‐1α in cerebrospinal fluid (CSF) and serum and then further evaluated whether MIP‐1α levels correlate with the severity and progression of ALS.
Methods
We used ELISAs to detect MIP‐1α levels from 58 patients with ALS and 45 age‐ and gender‐matched controls. The patients with ALS were also clinically evaluated with the revised ALS functional rating scale (ALSFRS‐r). Moreover, we followed up with 40 cases of ALS by way of call or clinic visit 4 years after enrollment in this study. Finally, we assessed the correlations between MIP‐1α levels and various clinical parameters.
Results
We found that the levels of MIP‐1α in patients with ALS significantly increased compared to controls and they were positively correlated with duration. MIP‐1α showed negative correlations with disease progression rate and the decrease in ALSFRS‐r. Furthermore, the cumulative survival of patients with ALS with high levels of MIP‐1α exceeded patients with low MIP‐1α levels.
Conclusions
MIP‐1α levels increased in both CSF and serum of patients with ALS, and it may be a potential neuroprotective biomarker in ALS.
Wiley Online Library